前收市價 | 18.85 |
開市 | 18.94 |
買盤 | 19.01 x 1300 |
賣出價 | 19.25 x 3100 |
今日波幅 | 18.94 - 19.26 |
52 週波幅 | 17.82 - 27.80 |
成交量 | |
平均成交量 | 17,023,236 |
市值 | 36.608B |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 21.24 |
每股盈利 (最近 12 個月) | 0.90 |
業績公佈日 | 無 |
遠期股息及收益率 | 0.80 (4.18%) |
除息日 | 2024年5月07日 |
1 年預測目標價 | 22.09 |
J&J is doubling down on medtech, a typically sleepy sector that has been risky, as it looks to grow after spinning of consumer health segment Kenvue.
At first glance, a concerted focus on stable blue-chip stocks might seem excessively cautious. After all, the market is booming, companies are hiring and people are spending. Don’t readily believe everything that you hear. No, I’m not advocating a doom-and-gloom narrative. However, there’s some evidence that a rotation out of the usual suspects – typically technology-related – is occurring, leading to other entities to play catch up. Yes, seemingly everyone loves artificial intelligence and what
While many, if not most investors, appear bullish about the market’s prospects this year, it’s never a bad time to consider long-term dividend stocks. By that, we’re talking about profitable, relevant enterprises that you can trust. These aren’t necessarily sexy securities but they should help you ride out any turbulence or even outright storms. Indeed, one of the main benefits of so-called unshakeable long-term dividend stocks centers on the psychological factor. So long as you’re targeting rel